Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 12
Submit an article Journal homepage
242
Views
4
CrossRef citations to date
0
Altmetric
Letters to the Editor

Infections in patients with lymphoproliferative diseases treated with brentuximab vedotin: SEIFEM multicentric retrospective study

Gessica Marchesinia Haematology Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5501-9620
ORCID Icon,
Gianpaolo Nadalia Haematology Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy
,
Davide Facchinellia Haematology Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, ItalyORCID Iconhttps://orcid.org/0000-0002-7581-5824
ORCID Icon,
Anna Candonib Division of Haematology and Stem Cell Transplantation, University Hospital of Udine, Udine, Italy
,
Chiara Cattaneoc Haematology Unit, Spedali Civili di Brescia, Brescia, Italy
,
Annarosa Cuccarod Institute of Haematology, Fondazione Policlinico A. Gemelli – IRCCS-Università Cattolica S. Cuore, Roma, ItalyORCID Iconhttps://orcid.org/0000-0002-0237-1839
ORCID Icon,
Rosa Fancie Haematology Unit, Careggi Hospital and University of Firenze, Florence, Italy
,
Francesca Farinaf Division of Haematology and Stem Cell Transplantation, IRCCS San Raffaele, Milano, Italy
,
Federica Lessig Division of Haematology and Clinical Immunology, University of Padova, Padova, Italy
,
Andrea Visenting Division of Haematology and Clinical Immunology, University of Padova, Padova, Italy
,
Francesco Marchesih Haematology and Stem Cell Transplantation Unit, Regina Elena National Cancer Institute, Roma, Italy
,
Lucia Preziosoi Haematology and BMT Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy
,
Angelica Spolzinoi Haematology and BMT Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy
,
Maria Chiara Tisij Division of Haematology, San Bortolo Hospital, Vincenza, Italy
,
Fabio Trastullik Department of Clinical Medicine and Surgery, Federico II University Medical School, Napoli, Italy
,
Luisa Vergal Haematology and CTA ASST Monza, Milano Bicocca University, Ospedale San Gerardo, Monza, Italy
,
Michela Dargeniom Haematology and Stem Cell Transplantation Unit, 'Vito Fazzi' Hospital, Lecce, Italy
,
Alessandro Buscan SSD Division of Haematology and Stem Cell Transplantation, A.O.U. Città della Salute, Torino, Italy
,
Livio Paganod Institute of Haematology, Fondazione Policlinico A. Gemelli – IRCCS-Università Cattolica S. Cuore, Roma, ItalyORCID Iconhttps://orcid.org/0000-0001-8287-928X
ORCID Icon & for Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) Group, Italy show all
Pages 3002-3005 | Received 07 May 2020, Accepted 15 Jun 2020, Published online: 01 Jul 2020

References

  • Muta H, Podack ER. CD30: from basic research to cancer therapy. Immunol Res. 2013;57(1–3):151–158.
  • Marin ND, Garcia LF. The role of CD30 and CD153 (CD30L) in the anti-mycobacterial immune response. Tuberculosis (Edinb). 2017;102:8–15.
  • Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853–1862.
  • Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555–566.
  • Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183–2189.
  • Nademanee A, Sureda A, Stiff P, et al. Safety analysis of brentuximab vedotin from the phase III AETHERA trial in Hodgkin lymphoma in the post-transplant consolidation setting. Biol Blood Marrow Transplant. 2018;24(11):2354–2359.
  • Sabet Y, Ramirez S, Rosell Cespedes E, et al. Severe acute pulmonary toxicity associated with brentuximab in a patient with refractory Hodgkin's lymphoma. Case Rep Pulmonol. 2016;2016:1–4.
  • Bassetti M, Pecori D, Righi E, et al. HSV-1 cutaneous infection in a patient with Hodgkin's lymphoma treated with brentuximab vedotin. J Chemother. 2013;25(6):381–382.
  • Gopal AK, Ramchandren R, O'Connor OA, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood. 2012;120(3):560–568.
  • De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813–1821.
  • Connors JM, Jurczak W, Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. N Engl J Med. 2018;378(4):331–344.
  • O'Connor OA, Lue JK, Sawas A, et al. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trial. Lancet Oncol. 2018;19(2):257–266.
  • Drgona L, Gudiol C, Lanini S, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). Clin Microbiol Infect. 2018;24(Suppl. 2):S83–S94.
  • Maschmeyer G, De Greef J, Mellinghoff SC, et al. Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL). Leukemia. 2019;33(4):844–862.
  • Ferreira AM, Ramos JF, Fatobene G, et al. Pneumocystis jirovecii pneumonia during brentuximab vedotin therapy: a case report and literature review. Case Rep Hematol. 2019;2019:8982937.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.